What was up is now down as smaller biotech stocks deal with clinical trial failure and acquisitions.
Survival data confirm the value of Astellas’s FLT3-targeting approach in acute myelogenous leukaemia.
UK group bets billions on an Her2 project slated for late-line patients and those with lower expression of the target protein.
Issues with manufacturing, not exactly a new problem for Immunomedics, derail the company’s bid for glory.
It could be hard for Macrogenics to shake off new safety concerns, whether it is the DART bispecific construct or its protein target that is to blame.
After years in the wilderness acute myeloid leukaemia is seeing a wave of activity, and there could be more targeted agents to come.
Turbulence in Japan made the country’s biopharma industry a relatively safe haven – but clinical success or setbacks dictated the fortunes of most mid and small-cap…
A non-profit partnership of 500 hospitals wants to deliver its first generic drugs in 2019, lowering prices and stabilising supplies.
Clinical progress – or the lack of it – underpins smaller biotechs' Q2 stock performance.